Search results
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 9 hours agoUnravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett Syndrome PR Newswire BOSTON, May 28, 2024 Initiation ...
Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial
FierceBiotech· 3 hours agoArrowhead Pharmaceuticals’ hotly anticipated cholesterol disorder drug lowered key lipoproteins that...
ORPHAN Cures | Pacific Sun
Pacific Sun· 6 days agoFor the roughly 30 million Americans living with a rare disease, the chances of finding an effective treatment are tragically slim. Adding insult to illness, an element of 2022’s Inflation Reduction ...
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Market Watch· 6 days agoThe drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S....
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Clinical Trials Arena via Yahoo Finance· 4 days agoFrom the dose level 1 cohort, there was one case of dose-limiting toxicity of febrile neutropenia....
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 hour agoHAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets ...
Zydus Lifesciences concludes subject enrolment in Phase II ALS trial
Clinical Trials Arena via Yahoo Finance· 4 days agoThe company has already established Phase II proof-of-concept in cryopyrin-associated periodic...
NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial...
The Woonsocket Call· 1 day agoNS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced today that it has received preliminary analysis results from the global Phase 3 clinical trial (RACER53 study ...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 5 days agoHI-Bio has plans to advance felzartamab into phase III for all indications. HI-Bio has received...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
KTLA-TV Los Angeles· 5 days agoPhase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 23, 2024 ...
